Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Matinas BioPharma Inc.

    AMEX: MTNB · Real-Time Price · USD
    0.94
    0.10 (11.90%)
    At close: Jun 16, 2025, 3:59 PM
    0.88
    -6.35%
    Pre-market: Jun 17, 2025, 08:48 AM EDT

    Matinas BioPharma Statistics

    Share Statistics

    Matinas BioPharma has 5.09M shares outstanding. The number of shares has increased by -97.97% in one year.

    Shares Outstanding

    n/a
    		 5.09M

    Shares Change (YoY)

    n/a
    		 -97.97%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 15.38%

    Shares Floating

    n/a
    		 4.56M

    Failed to Deliver (FTD) Shares

    n/a
    		 178

    FTD / Avg. Volume

    n/a
    		 0.11%

    Short Selling Information

    The latest short interest is 62.39K, so 1.23% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 62.39K

    Short % of Shares Out

    n/a
    		 1.23%

    Short % of Float

    n/a
    		 1.23%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -0.1 and the forward PE ratio is -0.17. Matinas BioPharma's PEG ratio is 0.02.

    PE Ratio

    n/a
    		 -0.1

    Forward PE

    n/a
    		 -0.17

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0

    PB Ratio

    n/a
    		 0.33

    P/FCF Ratio

    n/a
    		 -0.16

    PEG Ratio

    n/a
    		 0.02
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Matinas BioPharma.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.01, with a Debt / Equity ratio of 0.38.

    Current Ratio

    n/a
    		 3.01

    Quick Ratio

    n/a
    		 3.01

    Debt / Equity

    n/a
    		 0.38

    Debt / EBITDA

    n/a
    		 -0.12

    Debt / FCF

    n/a
    		 -0.18

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-8,083,666.67

    Employee Count

    n/a
    		 3

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -80K

    Effective Tax Rate

    n/a
    		 0.33%

    Stock Price Statistics

    The stock price has increased by -88.19% in the last 52 weeks. The beta is 1.3, so Matinas BioPharma's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.3

    52-Week Price Change

    n/a
    		 -88.19%

    50-Day Moving Average

    n/a
    		 0.71

    200-Day Moving Average

    n/a
    		 1.28

    Relative Strength Index (RSI)

    n/a
    		 58.36

    Average Volume (20 Days)

    n/a
    		 163,073

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -24.59M

    Net Income

    n/a
    		 -24.25M

    EBITDA

    n/a
    		 -23.36M

    EBIT

    n/a
    		 -24.33M

    Earnings Per Share (EPS)

    n/a
    		 -4.98
    Full Income Statement

    Balance Sheet

    The company has 7.28M in cash and 2.89M in debt, giving a net cash position of 4.39M.

    Cash & Cash Equivalents

    n/a
    		 7.28M

    Total Debt

    n/a
    		 2.89M

    Net Cash

    n/a
    		 4.39M

    Retained Earnings

    n/a
    		 -199.82M

    Total Assets

    n/a
    		 12.04M

    Working Capital

    n/a
    		 5.29M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -15.88M and capital expenditures 0, giving a free cash flow of -15.88M.

    Operating Cash Flow

    n/a
    		 -15.88M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -15.88M

    FCF Per Share

    n/a
    		 -3.26
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    MTNB does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for MTNB.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Sep 3, 2024. It was a backward split with a ratio of 1:50.

    Last Split Date

    n/a
    		 Sep 3, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:50

    Scores

    Altman Z-Score

    n/a
    		 -26.83

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist